Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A brain meningioma that occurs during childhood.
Biomarker and diagnostic research for childhood brain meningioma has been reported in the published literature.
4 clinical trials registered, 2 recruiting. Interventions under study include other interventions and procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
113 publications have been identified in PubMed for childhood brain meningioma. Research spans Case Report / Case Series (26%), Review / Meta-Analysis (18%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 29 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 9:42 PM UTC
Research summaries | 20 | 18% |
Disease patterns and progression | 20 | 18% |
Laboratory research | 19 | 17% |
Testing and diagnosis research | 11 | 10% |
Clinical study results | 10 | 9% |
New treatment approaches | 3 | 3% |
Other research | 1 | 1% |
Mullins A (2026). [PMID: 42059000](https://pubmed.ncbi.nlm.nih.gov/42059000/). *Neurooncol Adv*. [Review / Meta-Analysis]
Hogg FRA (2026). [PMID: 41871435](https://pubmed.ncbi.nlm.nih.gov/41871435/). *J Neurosurg Pediatr*. [Basic Science / Preclinical]
Brady SW (2026). [PMID: 42001506](https://pubmed.ncbi.nlm.nih.gov/42001506/). *Cancer Discov*. [Epidemiology / Natural History]
Lusk EN (2026). [PMID: 42004902](https://pubmed.ncbi.nlm.nih.gov/42004902/). *Mol Genet Metab Rep*. [Review / Meta-Analysis]
Germano IM (2026). [PMID: 42221984](https://pubmed.ncbi.nlm.nih.gov/42221984/). *Neurooncol Adv*. [Review / Meta-Analysis]
Rajan S (2026). [PMID: 41569358](https://pubmed.ncbi.nlm.nih.gov/41569358/). *Neuro-oncology*. [Case Report / Case Series]
Capellán-Martín D (2026). [PMID: 42099437](https://pubmed.ncbi.nlm.nih.gov/42099437/). *Segmentation Classif Synth Brain Tumors Trauma Brain Inj (2025)*. [Diagnostic / Biomarker]
Almeida ND (2026). [PMID: 41660311](https://pubmed.ncbi.nlm.nih.gov/41660311/). *Surgical neurology international*. [Review / Meta-Analysis]
Hug EB (2026). [PMID: 41488407](https://pubmed.ncbi.nlm.nih.gov/41488407/). *International journal of particle therapy*. [Clinical Trial Publication]
Park S (2026). [PMID: 40742239](https://pubmed.ncbi.nlm.nih.gov/40742239/). *American journal of clinical oncology*. [Case Report / Case Series]
AI-curated news mentioning childhood brain meningioma
Updated Aug 24, 2026
Five patients were found to have small masses on their spines. Regenxbio has faced previous safety concerns with its gene therapies. The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged. Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. The Food and Drug Administration has again paused trials for Regenxbio’s gene therapy for a rare childhood brain disorder, after small masses were found on the spines of five patients, the company said Monday. It was the first tumor to be conclusively linked to AAV gene therapy, the form of gene therapy most commonly used over the past 20 years. ... Savings start at 25%! ... To read the rest of this story subscribe to STAT+. Subscribe ... Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease.